I believe [this treatment strategy] is the future [for CSCC]. Perioperative treatment in melanoma is strong; I don't see any reason why it should not be as strong in CSCC and, eventually, other skin cancers. What is the role of anti–PD-1 agents in the neoadjuvant setting? We have ...
for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatme...
Lastly, there is not sufficient evidence for PNI in mSCC to suggest that surgery alone is equivocal to surgery and adjuvant radiotherapy. The lack of prospective trials greatly limits the recommendations that can be made regarding treatment decisions....
KEYTRUDA, in combination with axitinib, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC). KEYTRUDA is indicated for the adjuvant treatment of patients with RCC at...
Dr Patel on the Potential for Adjuvant Immunotherapy in CSCC Dr Petrella on Selecting Frontline Therapy in Metastatic Melanoma Dr Hamid on the Potential for Cancer Vaccines in Melanoma Dr Orloff on Treatment Strategies for Rapidly Progressing Uveal Melanoma Dr Faries on Emerging CAR T-Cell and TCR...
Other investigators have also studied low-dose alpha-interferon as surgicaladjuvant treatment for stage II melanoma. Low-dose alpha-interferon wasevaluated in a large, randomized study of adjuvant therapy in 499 patients withstage II melanoma (primary melanoma greater than 1.5 mm in thickness withclin...
L as a potential new and important cancer vaccine for patients with localized melanoma," said Alan Yu, chairman of Polynoma and vice president and chief operating officer at CK Life Sciences. "We look forward to advancing seviprotimut-L in a pivotal trial as an adjuvant treat...
Cemiplimab is an anti-programmed cell-death protein 1 inhibitor and the first immunotherapeutic agent approved for the treatment of metastatic or locally advanced cSCC. The purpose of this study was to evaluate the efficacy of cemiplimab when used as adjuvant or neoadjuvant therapy in patients ...
National Comprehensive Cancer Network (NCCN) recommendations for adjuvant radiation therapy (ART) use are similar for High Risk and Very High Risk cutaneous squamous cell carcinoma (cSCC) with negative post-surgical margins. Although studies report reductions in disease progression following ART treatment...
Better treatment options are needed for patients who experience recurrence after surgery. The PD-1 inhibitors pembrolizumab (pembro) and cemiplimab have shown durable antitumor activity in advanced metastatic cSCC. The randomized, double-blind, placebo-controlled, phase 3 KEYNOTE-630 (NCT03833167) ...